Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Cgix vc oct2013


Published on

Cancer Genetics Investor Info

  • Be the first to comment

  • Be the first to like this

Cgix vc oct2013

  1. 1. Cancer Genetics, Inc. (NASDAQ: CGIX)
  2. 2. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forwardlooking statements. In addition, the offering is subject to market and other conditions and there can be no assurance as to the estimated proceeds from the offering and the anticipated use of proceeds from the offering. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended June 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
  3. 3. Stock Basics Ticker CGIX Exchange NASDAQ Recent Price $14.13 Shares Outstanding 6.00 million (8.86 million post-closing) Market Cap $84.78 million ($125.19 million post-closing) Revenue – Trailing 12-mths $5.4 million YoY Revenue Growth (Q2) 60%
  4. 4. Recent Events • Raised $40 million in new investor capital • Significant investor interest from major healthcare funds and money managers • Recent analyst coverage (pre-financing) puts stock between $25-$30 per share Upcoming Catalytic Events • Ongoing relationship with Gilead Sciences • New data expected from Cleveland Clinic supporting renal array franchise • Anticipating Q4 launch of FHACT in the U.S. • FHACT is a blockbuster diagnostic for cervical cancer